Pseudomyxoma peritonei surgery: Difference between revisions
Jump to navigation
Jump to search
Nima Nasiri (talk | contribs) |
Nima Nasiri (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Surgery== | ==Surgery== | ||
*Surgery is the mainstay of treatment for pseudomyxoma peritonei. The feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis. | *Surgery is the mainstay of treatment for pseudomyxoma peritonei. The feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis. | ||
*A more aggressive approach by Sugarbaker utilizes peritonectomy and visceral resections, called cytoreductive surgery (CRS), in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) that is featured by direct targeting of the microscopic disease, locoregional drug availability, minimal systemic exposure and improved drug penetration through hyperthermia.<ref name="pmid19567401">{{cite journal |vauthors=Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M |title=Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience |journal=In Vivo |volume=23 |issue=4 |pages=639–44 |date=2009 |pmid=19567401 |doi= |url=}}</ref><ref name="pmid21874418">{{cite journal |vauthors=Kitai T, Kawashima M, Yamanaka K, Ichijima K, Fujii H, Mashima S, Shimahara Y |title=Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals |journal=Surg. Today |volume=41 |issue=9 |pages=1219–23 |date=September 2011 |pmid=21874418 |doi=10.1007/s00595-010-4495-6 |url=}}</ref> | *A more aggressive approach by Sugarbaker utilizes peritonectomy and visceral resections, called cytoreductive surgery (CRS), in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) that is featured by direct targeting of the microscopic disease, locoregional drug availability, minimal systemic exposure and improved drug penetration through hyperthermia.<ref name="pmid19567401">{{cite journal |vauthors=Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M |title=Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience |journal=In Vivo |volume=23 |issue=4 |pages=639–44 |date=2009 |pmid=19567401 |doi= |url=}}</ref><ref name="pmid21874418">{{cite journal |vauthors=Kitai T, Kawashima M, Yamanaka K, Ichijima K, Fujii H, Mashima S, Shimahara Y |title=Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals |journal=Surg. Today |volume=41 |issue=9 |pages=1219–23 |date=September 2011 |pmid=21874418 |doi=10.1007/s00595-010-4495-6 |url=}}</ref><ref name="pmid19567401">{{cite journal |vauthors=Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M |title=Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience |journal=In Vivo |volume=23 |issue=4 |pages=639–44 |date=2009 |pmid=19567401 |doi= |url=}}</ref> | ||
== References == | == References == | ||
Revision as of 16:19, 14 January 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei surgery On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei surgery |
|
Risk calculators and risk factors for Pseudomyxoma peritonei surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Surgery is the mainstay of treatment for pseudomyxoma peritonei. The feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis.[1][2]
Surgery
- Surgery is the mainstay of treatment for pseudomyxoma peritonei. The feasibility of surgery depends on the stage of pseudomyxoma peritonei at diagnosis.
- A more aggressive approach by Sugarbaker utilizes peritonectomy and visceral resections, called cytoreductive surgery (CRS), in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) that is featured by direct targeting of the microscopic disease, locoregional drug availability, minimal systemic exposure and improved drug penetration through hyperthermia.[3][4][3]
References
- ↑ Amini, Afshin; Masoumi-Moghaddam, Samar; Ehteda, Anahid; Morris, David (2014). "Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects". Orphanet Journal of Rare Diseases. 9 (1): 71. doi:10.1186/1750-1172-9-71. ISSN 1750-1172.
- ↑ Harmon R, Sugarbaker P (2005). "Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer". Int Semin Surg Oncol. 2 (1): 3. PMID 15701175.
- ↑ 3.0 3.1 Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M (2009). "Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience". In Vivo. 23 (4): 639–44. PMID 19567401.
- ↑ Kitai T, Kawashima M, Yamanaka K, Ichijima K, Fujii H, Mashima S, Shimahara Y (September 2011). "Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals". Surg. Today. 41 (9): 1219–23. doi:10.1007/s00595-010-4495-6. PMID 21874418.